Additionally, the AWARD-7 trial (Dulaglutide versus insulin glargine in patients with type 2 diabetes and CKD) demonstrated a reduction in insulin use among patients treated with dulaglutide as well as a lower incidence of the combined endpoint of progression to ESKD or a reduction in glomerular filtration rate [78]. The gene discussed is INS; the disease is type 2 diabetes mellitus.